45 CFR § 180 compliance
F · 50
This hospital published little of what § 180 requires.
●Machine-readable file published: assessment threshold met
○Gross / standard charges: below assessment threshold
●Discounted cash price: assessment threshold met
○Payer-specific negotiated rates: below assessment threshold
○Min / max negotiated charges: below assessment threshold
●Free, public, no login required: assessment threshold met
Procedures listed
43,772
Insurances with rates
6
CPT / HCPCS codes
10,322
Most expensive procedures (gross)
50242009606
$187,103
faricimab ophthalmic svoa 6 mg/0.05 mL Soln
Gross
$187,103
50242008001
$170,138
ranibizumab ophthalmic 10 mg/mL Soln
Gross
$170,138
50242008003
$163,332
ranibizumab ophthalmic 10 mg/mL Soln
Gross
$163,332
61755005001
$157,050
aflibercept ophthalmic 114.3 mg/mL Soln
Gross
$157,050
61755000502
$154,956
aflibercept ophthalmic 40 mg/mL Soln
Gross
$154,956
61755000501
$154,956
aflibercept ophthalmic 40 mg/mL Soln
Gross
$154,956
78082760
$154,956
brolucizumab ophthalmic dbll 6 mg/0.05 mL Soln
Gross
$154,956
78082761
$154,956
brolucizumab ophthalmic dbll 6 mg/0.05 mL Soln
Gross
$154,956
70114044101
$113,914
ranibizumab ophthalmic eqrn 10 mg/ml Soln
Gross
$113,914
82705001001
$103,596
epcoritamab bysp 48 mg/0.8 mL Soln
Gross
$103,596
15054112004
$100,057
lanreotide 120 mg/0.5 mL Soln
Gross
$100,057
50242008202
$97,999
ranibizumab ophthalmic 6 mg/mL Soln
Gross
$97,999
50242008203
$97,999
ranibizumab ophthalmic 6 mg/mL Soln
Gross
$97,999
69097087067
$93,053
lanreotide 120 mg/0.5 mL Soln
Gross
$93,053
73606002001
$91,717
pegcetacoplan ophthalmic 150 mg/mL Soln
Gross
$91,717
RAD97182
$70,982
N YT TRIUM-90 (ZEVALIN)
Gross
$88,727
78073461
$88,704
canakinumab 150 mg/mL Soln
Gross
$88,704
75987013015
$85,711
teprotumumab trbw 500 mg REC I
Gross
$85,711
50242008201
$81,666
ranibizumab ophthalmic 6 mg/mL Soln
Gross
$81,666
50242010501
$81,619
polatuzumab vedotin 140 mg REC I
Gross
$81,619
70114044001
$68,348
ranibizumab ophthalmic eqrn 6 mg/ml Soln
Gross
$68,348
24582411
$65,534
cabazitaxel 60 mg Soln
Gross
$65,534
59572077501
$56,480
luspatercept aamt 75 mg REC I
Gross
$56,480
RAD20335
$43,566
CL PACEMAKER/DEFIB W/LEAD
Gross
$54,458
RAD98445
$42,520
ZC IMPELLA 2.5 CATHETER
Gross
$53,150
RAD20380
$41,400
CL RENAL DENERVATION PERC UNILATE
Gross
$51,750
RAD20381
$41,400
CL RENAL DENERVATION PERC BILATER
Gross
$51,750
51144005001
$50,750
brentuximab vedotin 50 mg REC I
Gross
$50,750
RAD19783
$40,117
IR FEM/POP ATHEREC SF PRIMARY
Gross
$50,146
RAD19785
$40,117
IR FEM/POP ATHEREC CX PRIMARY
Gross
$50,146
RAD19787
$40,117
IR FEM/POP STENT/ATHEREC SF PRIMA
Gross
$50,146
RAD19789
$40,117
IR FEM/POP STENT/ATHEREC CX PRIMA
Gross
$50,146
RAD19796
$40,117
IR TIB/PER STENT SF PRIMARY
Gross
$50,146
RAD19798
$40,117
IR TIB/PER STENT CX PRIMARY
Gross
$50,146
RAD19800
$40,117
IR TIB/PER ATHEREC SF PRIMARY
Gross
$50,146
RAD19802
$40,117
IR TIB/PER ATHEREC CX PRIMARY
Gross
$50,146
RAD19804
$40,117
IR TIB/PER STENT/ATHEREC SF PRIMA
Gross
$50,146
RAD19806
$40,117
IR TIB/PER STENT/ATHEREC CX PRIMA
Gross
$50,146
RAD20385
$40,117
CL CORONARY STENT 2 OR MORE DISTI
Gross
$50,146
RAD20372
$39,606
CL PACEMAKER/DEFIBRILLATOR PLCMNT
Gross
$49,507
RAD20374
$39,606
CL BIVENTRICULAR PACEMAKER/DEFIBR
Gross
$49,507
55292070255
$49,121
hemin 350 mg REC I
Gross
$49,121
8451001
$47,594
gemtuzumab ozogamicin 4.5 mg REC I
Gross
$47,594
50242008527
$46,043
alteplase 100 mg REC
Gross
$46,043
RAD20349
$36,090
CL INS VENT ASSIST DEV PERC ART
Gross
$45,113
RAD20352
$36,090
CL INS VENT ASSIST DEV PERC ART/V
Gross
$45,113
RAD19740
$35,787
IR IVL STENT+PTA SAME VES LOWEXTR
Gross
$44,734
RAD19741
$35,787
IR IVL ATH+PTA SAME VES LOWEXTR N
Gross
$44,734
RAD19742
$35,787
IR IVL STENT+ATH+PTA SAMVES NOT T
Gross
$44,734
RAD19744
$35,787
IR IVL W/STENT+PTA SAM VES TIB/PE
Gross
$44,734
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 50242009606 | faricimab ophthalmic svoa 6 mg/0.05 mL Soln | $187,103 | $187,103 | — | — | 0 |
| 50242008001 | ranibizumab ophthalmic 10 mg/mL Soln | $170,138 | $170,138 | — | — | 0 |
| 50242008003 | ranibizumab ophthalmic 10 mg/mL Soln | $163,332 | $163,332 | — | — | 0 |
| 61755005001 | aflibercept ophthalmic 114.3 mg/mL Soln | $157,050 | $157,050 | — | — | 0 |
| 61755000502 | aflibercept ophthalmic 40 mg/mL Soln | $154,956 | $154,956 | — | — | 0 |
| 61755000501 | aflibercept ophthalmic 40 mg/mL Soln | $154,956 | $154,956 | — | — | 0 |
| 78082760 | brolucizumab ophthalmic dbll 6 mg/0.05 mL Soln | $154,956 | $154,956 | — | — | 0 |
| 78082761 | brolucizumab ophthalmic dbll 6 mg/0.05 mL Soln | $154,956 | $154,956 | — | — | 0 |
| 70114044101 | ranibizumab ophthalmic eqrn 10 mg/ml Soln | $113,914 | $113,914 | — | — | 0 |
| 82705001001 | epcoritamab bysp 48 mg/0.8 mL Soln | $103,596 | $103,596 | — | — | 0 |
| 15054112004 | lanreotide 120 mg/0.5 mL Soln | $100,057 | $100,057 | — | — | 0 |
| 50242008202 | ranibizumab ophthalmic 6 mg/mL Soln | $97,999 | $97,999 | — | — | 0 |
| 50242008203 | ranibizumab ophthalmic 6 mg/mL Soln | $97,999 | $97,999 | — | — | 0 |
| 69097087067 | lanreotide 120 mg/0.5 mL Soln | $93,053 | $93,053 | — | — | 0 |
| 73606002001 | pegcetacoplan ophthalmic 150 mg/mL Soln | $91,717 | $91,717 | — | — | 0 |
| RAD97182 | N YT TRIUM-90 (ZEVALIN) | $88,727 | $70,982 | — | — | 0 |
| 78073461 | canakinumab 150 mg/mL Soln | $88,704 | $88,704 | — | — | 0 |
| 75987013015 | teprotumumab trbw 500 mg REC I | $85,711 | $85,711 | — | — | 0 |
| 50242008201 | ranibizumab ophthalmic 6 mg/mL Soln | $81,666 | $81,666 | — | — | 0 |
| 50242010501 | polatuzumab vedotin 140 mg REC I | $81,619 | $81,619 | — | — | 0 |
| 70114044001 | ranibizumab ophthalmic eqrn 6 mg/ml Soln | $68,348 | $68,348 | — | — | 0 |
| 24582411 | cabazitaxel 60 mg Soln | $65,534 | $65,534 | — | — | 0 |
| 59572077501 | luspatercept aamt 75 mg REC I | $56,480 | $56,480 | — | — | 0 |
| RAD20335 | CL PACEMAKER/DEFIB W/LEAD | $54,458 | $43,566 | — | — | 0 |
| RAD98445 | ZC IMPELLA 2.5 CATHETER | $53,150 | $42,520 | — | — | 0 |
| RAD20380 | CL RENAL DENERVATION PERC UNILATE | $51,750 | $41,400 | — | — | 0 |
| RAD20381 | CL RENAL DENERVATION PERC BILATER | $51,750 | $41,400 | — | — | 0 |
| 51144005001 | brentuximab vedotin 50 mg REC I | $50,750 | $50,750 | — | — | 0 |
| RAD19783 | IR FEM/POP ATHEREC SF PRIMARY | $50,146 | $40,117 | — | — | 0 |
| RAD19785 | IR FEM/POP ATHEREC CX PRIMARY | $50,146 | $40,117 | — | — | 0 |
| RAD19787 | IR FEM/POP STENT/ATHEREC SF PRIMA | $50,146 | $40,117 | — | — | 0 |
| RAD19789 | IR FEM/POP STENT/ATHEREC CX PRIMA | $50,146 | $40,117 | — | — | 0 |
| RAD19796 | IR TIB/PER STENT SF PRIMARY | $50,146 | $40,117 | — | — | 0 |
| RAD19798 | IR TIB/PER STENT CX PRIMARY | $50,146 | $40,117 | — | — | 0 |
| RAD19800 | IR TIB/PER ATHEREC SF PRIMARY | $50,146 | $40,117 | — | — | 0 |
| RAD19802 | IR TIB/PER ATHEREC CX PRIMARY | $50,146 | $40,117 | — | — | 0 |
| RAD19804 | IR TIB/PER STENT/ATHEREC SF PRIMA | $50,146 | $40,117 | — | — | 0 |
| RAD19806 | IR TIB/PER STENT/ATHEREC CX PRIMA | $50,146 | $40,117 | — | — | 0 |
| RAD20385 | CL CORONARY STENT 2 OR MORE DISTI | $50,146 | $40,117 | — | — | 0 |
| RAD20372 | CL PACEMAKER/DEFIBRILLATOR PLCMNT | $49,507 | $39,606 | — | — | 0 |
| RAD20374 | CL BIVENTRICULAR PACEMAKER/DEFIBR | $49,507 | $39,606 | — | — | 0 |
| 55292070255 | hemin 350 mg REC I | $49,121 | $49,121 | — | — | 0 |
| 8451001 | gemtuzumab ozogamicin 4.5 mg REC I | $47,594 | $47,594 | — | — | 0 |
| 50242008527 | alteplase 100 mg REC | $46,043 | $46,043 | — | — | 0 |
| RAD20349 | CL INS VENT ASSIST DEV PERC ART | $45,113 | $36,090 | — | — | 0 |
| RAD20352 | CL INS VENT ASSIST DEV PERC ART/V | $45,113 | $36,090 | — | — | 0 |
| RAD19740 | IR IVL STENT+PTA SAME VES LOWEXTR | $44,734 | $35,787 | — | — | 0 |
| RAD19741 | IR IVL ATH+PTA SAME VES LOWEXTR N | $44,734 | $35,787 | — | — | 0 |
| RAD19742 | IR IVL STENT+ATH+PTA SAMVES NOT T | $44,734 | $35,787 | — | — | 0 |
| RAD19744 | IR IVL W/STENT+PTA SAM VES TIB/PE | $44,734 | $35,787 | — | — | 0 |
Showing top 50 of 43,772 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.